Summarized by Masters of Longevity from PR Newswire.
Phase 1 data show PROT-001 was tolerated and stabilized amyloidogenic lambda light chains.

Key Takeaways
- PROT-001 was generally safe and reached stabilizing plasma levels.
- PROT-001 reduced BNP and troponin in cardiomyocyte tests.
- Early NT-proBNP reductions were reported within 28 days.



